Actively Recruiting
Phase II Study of Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma
Led by Massachusetts General Hospital · Updated on 2026-01-14
50
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination of four drugsisatuximab, belantamab mafodotin, pomalidomide, and dexamethasonein people with relapsed and refractory multiple myeloma, a type of cancer. This phase II study aims to determine the overall response rate to this treatment combination. About 50 participants will be involved, and treatment will continue until the disease progresses, side effects occur, or participants choose to withdraw. Participants will receive isatuximab by intravenous infusion daily during the first 28-day cycle on days 1, 8, 15, and 22, then on days 1 and 15 of subsequent cycles. Belantamab mafodotin will be given intravenously every eight weeks after isatuximab infusion. Pomalidomide is taken orally once daily on days 1 through 21 of each cycle, while dexamethasone is taken orally on specific days within each cycle. Participants will keep drug diaries to record their intake of pomalidomide and dexamethasone. Throughout the study, participants will undergo assessments to monitor their response to treatment, including measuring the overall response rate four weeks after treatment starts. Researchers will also track adverse events, progression-free survival for up to 10 years, and overall survival. Study visits include clinical evaluations and monitoring to ensure safety and treatment adherence. The study began in May 2024 and is expected to continue until the end of 2030.
CONDITIONS
Brief Title
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Research Team
A
Andrew Yee, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here